Company
Cytuvax
- Biotech
- Location:
- Maastricht, Netherlands
Description
Cytuvax develops cancer immunotherapy and vaccines for viral and bacterial pathogens, using depot-attached cytokines as immune-stimulating adjuvants to improve dendritic-cell antigen presentation and activate humoral and cellular immune responses.
Cytuvax is located in the Netherlands ecosystem.
Related
OsivaxOsivax develops oligoDOM self-assembling nanoparticle vaccines that activate T-cell and B-cell immunity for broader protection against…
CimCureCimCure develops cancer vaccines using its proprietary iBoost conjugate technology to induce immune responses that target and destroy…
- Asgard TherapeuticsAsgard Therapeutics develops AT-108, an off-the-shelf gene therapy using direct cell reprogramming to activate professional…
- CeraVxCeraVx develops ceramic CeraMaps microneedle patches for intradermal delivery of vaccines and medicines, using biocompatible, inert…
- BelynticBelyntic develops T-Fender vaccines that use self-adjuvant, self-aggregating synthetic long peptides, combined with AI-based prediction, to…
CytovationCytovation develops CyPep-1, a tumor membrane-targeted immunotherapy, using peptide engineering to activate immune recognition and tumor…
CiMaasCiMaas develops immunotherapy products that expand and engineer natural killer (NK) cells for adoptive cell therapy and CAR‑NK applications…
Faron PharmaceuticalsFaron Pharmaceuticals creates cancer treatments that use patients’ immune systems, with bexmarilimab, an anti-Clever-1 antibody and myeloid…
ORF GeneticsORF Genetics produces animal-free, plant-made recombinant growth factors and cytokines used to support human cell cultures, skincare…